NF1相关神经纤维瘤术语共识与MEK抑制剂应用基础
德国NF工作组通过改良德尔菲法形成多学科共识,统一NF1相关神经纤维瘤尤其是丛状神经纤维瘤的术语。共识将术语与影像、病理、手术、活检及药物治疗相关联,提出整合解剖与组织学描述的新分类框架,以改善跨学科沟通并为MEK抑制剂应用提供基础。
要点
- NF1相关神经纤维瘤术语缺乏统一,影响影像报告与临床沟通。
- 新术语框架整合解剖与组织学描述,重点规范丛状神经纤维瘤。
- 统一术语有助于筛选适合MEK抑制剂治疗的丛状神经纤维瘤患者。
核心结论
- 多学科共识提出NF1相关神经纤维瘤的结构化术语框架,整合解剖与组织学描述,以改善跨学科沟通并为MEK抑制剂应用提供一致基础。
研究设计与样本
- 德国NF工作组采用改良德尔菲法形成多学科专家共识,围绕神经纤维瘤定义、分类及其在影像、病理、手术、活检和药物治疗中的相关性制定声明。
诊断标准与关键数值
- 共识提出新的NF结构化术语,将解剖描述与组织学描述整合用于神经纤维瘤分类,重点针对丛状神经纤维瘤。
- 共识声明涵盖神经纤维瘤的定义与分类及其对影像、病理、手术、活检和药物治疗的相关性,未报告具体敏感度、特异度、AUC或阈值数值。
临床应用与阅片要点
- 放射科与超声科医生可采用共识术语描述NF1相关神经纤维瘤,减少报告用词不一致。
- 影像描述应重点关注丛状神经纤维瘤的解剖范围与形态特征,为治疗决策提供依据。
- 统一术语有助于放射科与病理、外科及肿瘤科围绕MEK抑制剂适用性进行更准确的多学科沟通。
局限性
- 共识由德国NF工作组制定,未报告共识声明的证据分级或推荐等级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Neurofibromatosis type 1 (NF1) is characterized by the development of neurofibromas, including cutaneous neurofibromas and plexiform neurofibromas (PNFs). Despite more than a century of clinical recognition, the terminology used to describe these tumors remains inconsistent across disciplines, particularly in pathology, radiology, and clinical practice. This lack of standardized nomenclature complicates communication, diagnostic assessment, risk stratification, and therapeutic decision-making. In this multidisciplinary consensus paper, experts from the German NF Working Group sought to harmonize current terminology for NF1-associated neurofibromas, with particular emphasis on PNF, and to relate this terminology to diagnostic procedures, clinical course, and treatment considerations. A new structured terminology of NF integrating anatomic and histological descriptions is proposed. Using a modified Delphi process, the group developed consensus statements addressing the definition and classification of neurofibromas and their relevance for imaging, pathology, surgery, biopsy, and medical treatment. A unified terminology is especially important in the era of targeted therapy, as MEK inhibitors have emerged as a promising treatment option for selected patients with NF1-associated PNF. Establishing a shared conceptual framework may improve interdisciplinary communication, support more consistent clinical decision-making, and provide a stronger basis for future recommendations on the use of MEK inhibitors in NF1.
引用
- Baldino, Koeppen, Kammermeier, et al. Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors. Anticancer Res. 2026. PMID: 42674696. doi:10.21873/anticanres.18332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。